DLL3 and small cell lung carcinoma: Fourth, while DLL3-targeted agents (e.g., Amgen’s tarlatamab) have achieved breakthroughs in small cell lung cancer treatment, drug resistance remains problematic, and biomarker selection systems require optimization Fifth, although natural compounds like quercetin show specific Notch pathway modulatory activity, their low bioavailability presents a significant challenge.